Literature DB >> 32641127

Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China.

Qi Zhao1, Ting-Yu Zhang1, Yu-Jing Cheng1, Yue Ma2, Ying-Kai Xu1, Jia-Qi Yang1, Yu-Jie Zhou3.   

Abstract

BACKGROUND: The relationship between triglyceride-glucose index (TyG index) and the prevalence and prognosis of cardiovascular disease has been confirmed by former studies. However, it remains uncertain whether TyG index has a prognostic impact in patients with type 2 diabetes mellitus (T2DM) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI).
METHODS: The study retrospectively enrolled 798 patients (mean age: 60.9 ± 8.3 years; 68.3% men) with T2DM and NSTE-ACS who underwent PCI at Beijing Anzhen Hospital from January to December 2015. TyG index was calculated as previously reported: ln [fasting TGs (mg/dL) * FBG (mg/dL)/2]. The primary endpoint was a composite of adverse events as follows: all-cause death, non-fatal myocardial infarction (MI) and ischemia-driven revascularization.
RESULTS: TyG index was significantly higher in patients with a primary endpoint event compared with those without. Multivariate Cox proportional hazards analysis showed that 1-unit increase of TyG index was independently associated with higher risk of primary endpoint, independent of other risk factors [hazard ratio (HR) 3.208 per 1-unit increase, 95% confidence interval (CI) 2.400-4.289, P < 0.001]. The addition of TyG index to a baseline risk model had an incremental effect on the predictive value for adverse prognosis [AUC: baseline risk model, 0.800 vs. baseline risk model + TyG index, 0.856, P for comparison < 0.001; category-free net reclassification improvement (NRI) 0.346, P < 0.001; integrated discrimination improvement (IDI) 0.087, P < 0.001].
CONCLUSIONS: Increased TyG index is a significant predictor of adverse prognosis in patients with T2DM and NSTE-ACS undergoing PCI. Further studies need to be performed to determine whether interventions for TyG index have a positive impact on improving clinical prognosis.

Entities:  

Keywords:  Non-ST-segment elevation acute coronary syndrome; Percutaneous coronary intervention; Triglyceride-glucose index; Type 2 diabetes mellitus

Year:  2020        PMID: 32641127     DOI: 10.1186/s12933-020-01086-5

Source DB:  PubMed          Journal:  Cardiovasc Diabetol        ISSN: 1475-2840            Impact factor:   9.951


  23 in total

Review 1.  Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis.

Authors:  Xiao Liu; Ziqi Tan; Yuna Huang; Huilei Zhao; Menglu Liu; Peng Yu; Jianyong Ma; Yujie Zhao; Wengen Zhu; Jingfeng Wang
Journal:  Cardiovasc Diabetol       Date:  2022-07-01       Impact factor: 8.949

2.  The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults.

Authors:  Ehsaneh Taheri; Mohammad Amin Pourhoseingholi; Alireza Moslem; Amir Hossein Hassani; Alireza Mousavi Jarrahi; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali; Behzad Hatami
Journal:  J Diabetes Metab Disord       Date:  2022-01-11

3.  Triglyceride-glucose index linked to all-cause mortality in critically ill patients: a cohort of 3026 patients.

Authors:  Ying Liao; Rongting Zhang; Shanshan Shi; Yukun Zhao; Yibo He; Lihua Liao; Xueqin Lin; Qian Guo; Yani Wang; Liling Chen; Weiguo Li; Shihai Li; Kaihong Chen; Yong Fang
Journal:  Cardiovasc Diabetol       Date:  2022-07-08       Impact factor: 8.949

4.  Predictive effect of triglyceride‑glucose index on clinical events in patients with type 2 diabetes mellitus and acute myocardial infarction: results from an observational cohort study in China.

Authors:  Yue Zhang; Xiaosong Ding; Bing Hua; Qingbo Liu; Hui Gao; Hui Chen; Xue-Qiao Zhao; Weiping Li; Hongwei Li
Journal:  Cardiovasc Diabetol       Date:  2021-02-11       Impact factor: 9.951

5.  Triglyceride-glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort.

Authors:  Xue Tian; Yingting Zuo; Shuohua Chen; Qian Liu; Boni Tao; Shouling Wu; Anxin Wang
Journal:  Cardiovasc Diabetol       Date:  2021-01-12       Impact factor: 9.951

6.  Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus.

Authors:  Man Li; Lei Duan; Yulun Cai; Benchuan Hao; Jianqiao Chen; Huiying Li; Hongbin Liu
Journal:  Cardiovasc Diabetol       Date:  2021-02-19       Impact factor: 9.951

7.  Prognostic Significance of Triglyceride-Glucose Index for Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Authors:  Jin-Wen Luo; Wen-Hui Duan; Yan-Qiao Yu; Lei Song; Da-Zhuo Shi
Journal:  Front Cardiovasc Med       Date:  2021-12-02

8.  Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study.

Authors:  Ya-Wen Lu; Chun-Chin Chang; Ruey-Hsing Chou; Yi-Lin Tsai; Li-Kuo Liu; Liang-Kung Chen; Po-Hsun Huang; Shing-Jong Lin
Journal:  Cardiovasc Diabetol       Date:  2021-10-13       Impact factor: 9.951

9.  Association Between Triglyceride-Glucose Index and 2-Year Adverse Cardiovascular and Cerebrovascular Events in Patients with Type 2 Diabetes Mellitus Who Underwent Off-Pump Coronary Artery Bypass Grafting.

Authors:  Liang Chen; Xiao-Hang Ding; Kang-Jun Fan; Ming-Xin Gao; Wen-Yuan Yu; Hong-Li Liu; Yang Yu
Journal:  Diabetes Metab Syndr Obes       Date:  2022-02-16       Impact factor: 3.168

10.  Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study.

Authors:  Anxin Wang; Xue Tian; Yingting Zuo; Shuohua Chen; Xia Meng; Shouling Wu; Yongjun Wang
Journal:  Cardiovasc Diabetol       Date:  2021-05-26       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.